Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Incyte Corporation - Common Stock (NQ:INCY)

86.92 +0.76 (+0.88%)
Official Closing Price Updated: 4:15 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy Lawsuit
INCY Q2 Deep Dive: Product Launches and Pipeline Progress Underpin Revenue Growth
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 16.5% year on year to $1.22 billion. Its non-GAAP profit of... 
Via StockStory
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media... 
Via StockStory
Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer
Via Stocktwits
Earnings Scheduled For July 29, 2025
 
Via Benzinga
A Look at Incyte's Upcoming Earnings Report
 
Via Benzinga
Beyond The Numbers: 12 Analysts Discuss Incyte Stock
 
Via Benzinga
Incyte Corp (NASDAQ:INCY): A Value Investing Gem with Strong Valuation and Financial Stability
Incyte Corp (INCY) is a value investor's pick with a strong 9/10 Valuation Rating, low P/E ratios, solid financial health, and steady profitability in biotech. 
Via Chartmill
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria. 
Via Investor's Business Daily
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
 
Via Benzinga
The Analyst Verdict: Incyte In The Eyes Of 10 Experts
 
Via Benzinga
Top S&P500 movers in Tuesday's session
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
Incyte (INCY) Stock Trades Up, Here Is Why
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 10.4% in the afternoon session after the company reported second-quarter financial results that beat analyst expectations and... 
Via StockStory
Topics Artificial Intelligence
Uncover the latest developments among S&P500 stocks in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events. 
Via Benzinga
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand
Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development. 
Via Benzinga
Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Which S&P500 stocks are moving before the opening bell on Tuesday?
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
Incyte (NASDAQ:INCY) Reports Strong Q2
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q2 CY2025, with sales up 16.5% year on year to $1.22 billion. Its non-GAAP profit of $1.57 per share... 
Via StockStory
Incyte (INCY) Q2 Earnings: What To Expect
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be announcing earnings results this Tuesday morning. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
1 Value Stock Worth Your Attention and 2 Facing Headwinds
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Topics Supply Chain
INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Attractive Valuation
INCYTE CORP (NASDAQ:INCY) presents a value opportunity with strong profitability, financial health, and an undervalued forward P/E. Analysts expect earnings growth despite a slight revenue decline. 
Via Chartmill
3 Cash-Producing Stocks with Questionable Fundamentals
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
3 S&P 500 Stocks Skating on Thin Ice
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. 
Via StockStory
Topics Artificial Intelligence
Top S&P500 movers in Friday's session
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In
Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis. 
Via Stocktwits
Topics Intellectual Property
Uncover the latest developments among S&P500 stocks in today's session.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Thursday's session: top gainers and losers in the S&P500 index
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.